Nisa Investment Advisors
RCKT icon

Nisa Investment Advisors’s Rocket Pharmaceuticals RCKT Stock Holding History

Nisa Investment Advisors’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.1K Buy
4,133
+3,144
+318% +$10.5K ﹤0.01% 2375
2026
Q1 		$3.54K Buy
989
+56
+6% +$223 ﹤0.01% 2529
2025
Q4 		$3.27K Sell
933
-700
-43% -$2.4K ﹤0.01% 2527
2025
Q3 		$5.32K Buy
1,633
+118
+8% +$372 ﹤0.01% 2426
2025
Q2 		$3.71K Buy
1,515
+815
+116% +$4.13K ﹤0.01% 2495
2025
Q1 		$4.67K Sell
700
-2,287
-77% -$22.6K ﹤0.01% 2269
2024
Q4 		$37.5K Sell
2,987
-63
-2% -$948 ﹤0.01% 1760
2024
Q3 		$56.3K Sell
3,050
-110
-3% -$2.25K ﹤0.01% 1621
2024
Q2 		$68K Buy
3,160
+764
+32% +$17.5K ﹤0.01% 1575
2024
Q1 		$64.5K Buy
2,396
+56
+2% +$1.59K ﹤0.01% 1590
2023
Q4 		$70.1K Sell
2,340
-3
-0.1% -$66 ﹤0.01% 1540
2023
Q3 		$48K Sell
2,343
-197
-8% -$3.58K ﹤0.01% 1738
2023
Q2 		$50.5K Buy
2,540
+550
+28% +$11.1K ﹤0.01% 1745
2023
Q1 		$34K Sell
1,990
-141,000
-99% -$2.76M ﹤0.01% 1829
2022
Q4 		$2.8M Buy
142,990
+141,000
+7,085% +$2.6M 0.02% 627
2022
Q3 		$37K Buy
1,990
+290
+17% +$4.53K ﹤0.01% 1855
2022
Q2 		$23K Sell
1,700
-4,500
-73% -$53.6K ﹤0.01% 2014
2022
Q1 		$98K Sell
6,200
-1,160
-16% -$20K ﹤0.01% 1621
2021
Q4 		$122K Sell
7,360
-140
-2% -$3.82K ﹤0.01% 1443
2021
Q3 		$224K Hold
7,500
– – ﹤0.01% 1367
2021
Q2 		$332K Sell
7,500
-680
-8% -$29.5K ﹤0.01% 1252
2021
Q1 		$363K Buy
8,180
+400
+5% +$22K ﹤0.01% 1264
2020
Q4 		$427K Buy
7,780
+980
+14% +$35.7K ﹤0.01% 1218
2020
Q3 		$155K Buy
6,800
+1,500
+28% +$37K ﹤0.01% 1397
2020
Q2 		$111K Hold
5,300
– – ﹤0.01% 1416
2020
Q1 		$74K Hold
5,300
– – ﹤0.01% 1450
2019
Q4 		$121K Hold
5,300
– – ﹤0.01% 1405
2019
Q3 		$62K Hold
5,300
– – ﹤0.01% 1517
2019
Q2 		$80K Hold
5,300
– – ﹤0.01% 1454
2019
Q1 		$93K Hold
5,300
– – ﹤0.01% 1444
2018
Q4 		$79K Buy
+5,300
New +$88K ﹤0.01% 1392

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Nisa Investment Advisors's RCKT Position: Q2 2026 in Review

Nisa Investment Advisors increased its Rocket Pharmaceuticals (RCKT) stake by 318% in Q2 2026, buying an estimated $10.5K and bringing the position to 4,133 shares worth $14.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2375.

Nisa Investment Advisors first reported a position in RCKT in Q4 2018 and has held it in 31 quarters since. The position peaked at $2.8M in Q4 2022. 180 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

  • Nisa Investment Advisors held 4,133 shares of Rocket Pharmaceuticals worth $14.1K as of Q2 2026.
  • Nisa Investment Advisors bought 3,144 Rocket Pharmaceuticals shares in Q2 2026, an estimated $10.5K.
  • Rocket Pharmaceuticals made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q2 2026, its #2375 holding.
  • Nisa Investment Advisors first reported a position in Rocket Pharmaceuticals in Q4 2018 and has held it in 31 quarters since.
  • Nisa Investment Advisors's Rocket Pharmaceuticals position peaked at $2.8M in Q4 2022.
  • 180 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on Nisa Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.